These data suggest that TGF-β1 induction regulates the EMT and migration in selected subtypes of NSCLC cells with acquired resistance to EGFR-TKIs, and that TGF-β1 signaling blockade might reduce resistance to gefitinib. This evidence concerns the gene TGFB1 and non-small cell lung carcinoma.